Search Results
Your search for 3 matches 15623 pages
Showing 5251 - 5300Expert Point of View: Stephanie Berg, DO
The formal discussant of the CLEAR trial, Stephanie Berg, DO, of Loyola University Medical Center, Chicago, was enthusiastic about these findings. “Traditionally, first-line therapy with vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitors led to a median overall survival...
Lenvatinib/Pembrolizumab Combination Improves Outcomes vs Sunitinib in Renal Cell Carcinoma
The combination of lenvatinib plus pembrolizumab was superior to sunitinib for progression-free and overall survival as well as other key endpoints in patients with advanced clear cell renal cell carcinoma (RCC), according to results of the phase III CLEAR trial presented at the 2021 Genitourinary ...
Rates of Seroconversion Among Patients With Cancer Infected With COVID-19
Most people with cancer who are infected with COVID-19 produce antibodies at a rate comparable to the rest of the population—but their ability to do so depends on the type of malignancy and the treatments they’ve received, according to a new study published by Thakkar et al in Nature Cancer. The...
Adjuvant Atezolizumab in Muscle-Invasive Urothelial Carcinoma: IMvigor010
As reported in The Lancet Oncology by Joaquim Bellmunt, MD, PhD, and colleagues, the phase III IMvigor010 trial showed no improvement in disease-free survival with adjuvant atezolizumab vs observation in patients with muscle-invasive urothelial carcinoma. Study Details In the open-label trial, 809...
Expert Point of View: Sumanta Pal, MD
Sumanta Pal, MD, of City of Hope, Duarte, California, praised the authors for the conduct of the study, but stopped short of endorsing nivolumab as standard of care. “The phase III CheckMate 274 trial evaluated adjuvant nivolumab vs placebo in patients with high-risk, resected, muscle-invasive...
Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer
Adjuvant therapy with nivolumab, an anti–PD-1 immune checkpoint inhibitor, after radical surgery improved disease-free survival in high-risk muscle-invasive urothelial cancer regardless of PD-L1 status, according to the results of the CheckMate 274 randomized phase III trial presented at the 2021...
Olaparib for Previously Treated Patients With Pancreatic Cancer and DDR Genetic Alterations Other Than BRCA Variants
Combined results of two parallel phase II studies reported in JAMA Oncology by Milind Javle, MD, and colleagues indicated that olaparib may have therapeutic value in previously treated patients with platinum-sensitive pancreatic ductal carcinoma with DNA damage repair (DDR) genetic alterations...
Analysis From the International Germ Cell Cancer Collaborative Group Update Consortium
In an analysis of a modern cohort of patients with metastatic seminoma reported in the Journal of Clinical Oncology, Beyer et al, members of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update Consortium, found that progression-free and overall survival have improved compared...
FDA Approves Pembrolizumab Combination for Advanced Esophageal or Gastroesophageal Junction Carcinoma
On March 22, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) in combination with platinum and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (tumors with epicenter 1–5 cm above the...
Image-Guided Intensity-Modulated Radiotherapy in Patients With Cervical Cancer
Treatment with image-guided intensity-modulated radiotherapy (IG-IMRT) led to reduced late toxicities vs standard three-dimensional (3D) conformal radiotherapy in patients with cervical cancer, according to data presented by Supriya Chopra, MD, and colleagues during the Society of Gynecologic...
KRAS Mutation Status May Predict Outcomes After Hepatic Arterial Infusion Pump Therapy for Unresectable Colorectal Liver Metastases
KRAS mutational status in patients with unresectable liver metastases from colorectal cancer predicts a worse response to hepatic arterial infusion (HAI) pump chemotherapy, according to research presented by Kolbeinsson et al at the Society of Surgical Oncology 2021 International Conference on...
Niraparib Plus Bevacizumab Shows Clinical Benefit in Patients With Advanced Ovarian Cancer
The addition of niraparib maintenance to first-line platinum-based chemotherapy with bevacizumab demonstrated clinical benefit in patients with advanced ovarian cancer, according to data from the OVARIO study presented by Melissa M. Hardesty, MD, MPH, during the Society of Gynecologic Oncology...
First-Line TPEx vs EXTREME Regimen for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
In a phase II trial (GORTEC 2014-01 TPExtreme) reported in The Lancet Oncology, Joël Guigay, MD, and colleagues found that first-line TPEx (docetaxel/platinum/cetuximab) did not improve overall survival vs the standard-of-care EXTREME regimen (fluorouracil [5-FU]/platinum/cetuximab) in patients...
Benefit of Niraparib Maintenance Therapy Extends Beyond First Disease Progression in Recurrent Ovarian Cancer
The PARP (poly [ADP-ribose] polymerase) inhibitor niraparib is safe for long-term use and effective as maintenance treatment in patients with platinum-sensitive recurrent ovarian cancer, according to data presented by Ursula A. Matulonis, MD, at the Society of Gynecologic Oncology (SGO) 2021...
Frailty May Impact Surgical Outcomes in Patients With Ovarian Cancer
Frailty may be a better predictor of poor surgical outcomes in patients with ovarian cancer than age, according to two studies reported at the Society of Gynecologic Oncology (SGO) 2021 Virtual Annual Meeting on Women’s Cancer. Researchers found that frail patients are less likely to undergo...
PARP Inhibition Shows Efficacy in Ovarian Cancer Regardless of Number of Prior Lines of Chemotherapy, BRCA Mutation Status
Treatment with olaparib is safe and effective for patients with platinum-sensitive relapsed ovarian cancer, regardless of the number of prior lines of chemotherapy received and BRCA mutation status, according to data presented from the phase II LIGHT study by Karen A. Cadoo, MD, at the Society of...
Pembrolizumab/Lenvatinib May Improve Survival in Advanced Endometrial Cancer
In the first report from the pivotal phase III KEYNOTE-775/Study 309 trial, the combination of lenvatinib and pembrolizumab significantly improved multiple outcomes compared to standard single-agent chemotherapy in patients with advanced, metastatic, or recurrent endometrial cancer that had...
Utilization and Survival Benefit of Adjuvant Immunotherapy for Resected High-Risk Stage II Melanoma
An observational study of 10,592 patients from the National Cancer Database with stage IIB/IIC melanoma who had undergone surgical resection demonstrated a significant survival advantage with immunotherapy. The research was presented by Wong et al at the Society of Surgical Oncology 2021...
Association of Cardiovascular Risk Factors With Risk of Subsequent Cancer
In a study reported in JACC: CardioOncology, Emily S. Lau, MD, and colleagues found that the presence of cardiovascular disease risk factors was significantly associated with an increased risk of future cancer, although no increased risk was observed among individuals who had a history of...
Noncovalent BTK Inhibitor Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies
In the phase I/II BRUIN trial reported in The Lancet, Anthony R. Mato, MD, and colleagues found that the noncovalent Bruton’s tyrosine kinase (BTK) inhibitor pirtobrutinib produced durable responses in patients with relapsed or refractory B-cell malignancies, including those previously treated with ...
Immunotherapy Doublet as Maintenance Therapy for Extensive-Disease SCLC
As reported in the Journal of Clinical Oncology by Taofeek K. Owonikoko, MD, PhD, and colleagues, the phase III CheckMate 451 trial showed no improvement in overall survival with combined nivolumab and ipilimumab vs placebo as maintenance therapy for extensive-disease small cell lung cancer. Study ...
FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable Hepatocellular Carcinoma
Today, the U.S. Food and Drug Administration (FDA) approved TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma. The approval expands access to this therapy, which, to date, has been utilized under a humanitarian device exemption—an FDA...
Improving the Prognostic Accuracy of Residual Cancer Burden After Neoadjuvant Chemotherapy for Breast Cancer
An analysis of 546 patients with breast cancer who received neoadjuvant chemotherapy demonstrated that residual cancer burden is prognostic for overall survival, recurrence-free survival, and distant relapse–free survival, according to research presented by White et al at the Society of Surgical...
Umbralisib for Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
As reported in the Journal of Clinical Oncology by Nathan H. Fowler, MD, and colleagues, the phase IIb UNITY-NHL trial has shown that the dual PI3Kδ/casein kinase (CK) 1ε inhibitor umbralisib produced durable responses in patients with relapsed or refractory indolent non-Hodgkin lymphoma. The study ...
Updated Evidence Report and Systematic Review of Low-Dose CT Screening for Lung Cancer
In an analysis of updated evidence on low-dose computed tomography (CT) screening for lung cancer reported in JAMA, Jonas et al found that screening can reduce lung cancer mortality but may be associated with a range of potential harms. The analysis was performed to inform the new U.S. Preventive...
Pembrolizumab vs Chemotherapy in Previously Treated Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-119
As reported in The Lancet Oncology by Eric P. Winer, MD, FASCO, and colleagues, the phase III KEYNOTE-119 trial showed no significant improvement in overall survival with pembrolizumab vs investigator’s choice of chemotherapy in the second- or third-line treatment of metastatic triple-negative...
Study Identifies Factors That May Lower the Risk of CNS Relapse in Pediatric Patients With ALL
Starting chemotherapy several days before the first lumbar puncture for diagnosis and treatment of acute lymphoblastic leukemia (ALL) may reduce the risk of central nervous system (CNS) relapse in children, according to a study published by Tang et al in the journal Blood. The research focused on...
Persistent Use of Low-Value Breast Cancer Surgeries Designated for Deimplementation by Choosing Wisely
In a retrospective cohort study reported in JAMA Surgery, Wang et al found persistent use of low-value breast cancer surgeries designated for deimplementation by the Choosing Wisely program, with a wide interfacility variation in use of these procedures. Study Details The study used National Cancer ...
ROBUST Trial: Addition of Lenalidomide to R-CHOP in Previously Untreated ABC-Type DLBCL
As reported in the Journal of Clinical Oncology by Grzegorz S. Nowakowski, MD, and colleagues, the phase III ROBUST trial showed that the addition of lenalidomide to R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R2-CHOP) did not significantly improve...
Secondary Cytoreduction Plus Chemotherapy vs Chemotherapy Alone in Relapsed Platinum-Sensitive Epithelial Ovarian Cancer
In a Chinese phase III trial (SOC-1) reported in The Lancet Oncology, Shi et al found that secondary cytoreduction followed by chemotherapy significantly prolonged progression-free survival vs chemotherapy alone in patients with platinum-sensitive relapsed epithelial ovarian cancer. No significant...
Novel HER2-Targeted Therapies Pose Sequencing Challenges
With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setting and beyond, there are now at least eight HER2-targeted agents approved by the U.S. Food and Drug ...
CheckMate 9ER: First-Line Nivolumab Plus Cabozantinib vs Sunitinib for Advanced Renal Cell Carcinoma
As reported in The New England Journal of Medicine by Toni K. Choueiri, MD, and colleagues, the phase III CheckMate 9ER trial has shown that the combination of nivolumab and cabozantinib improved progression-free survival and overall survival vs sunitinib in first-line treatment of patients with...
Value of Global Scale-up of Cancer Care: Investment in Treatment, Imaging, and Quality of Care
In a simulation-based analysis reported in The Lancet Oncology, Ward et al found that the scaling up of cancer treatment packages, imaging modalities, and quality of care to the levels found in high-income countries would markedly reduce cancer mortality in low- to middle-income countries, as well...
High- vs Standard-Dose Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer
In a phase II trial reported in The Lancet Oncology, Grønberg et al found that use of high-dose vs standard-dose twice daily thoracic radiotherapy as part of first-line chemoradiotherapy was associated with significantly improved overall survival and similar toxicity in patients with limited-stage...
International Perspectives on Integrative Medicine for Cancer Prevention and Management
Guest Editor’s Note: Although many cancer centers recognize the value of integrative therapies in oncologic care, cancer prevention, its treatment, and survivorship care continue to pose a challenge in many low- and middle-income countries. In this article, Alejandro Salicrup, PhD, highlights the...
New Survey Reveals Hesitancy Around COVID-19 Vaccination Among Patients With Hematologic Malignancies and Survivors
A survey of more than 6,500 U.S. patients with blood cancer and survivors revealed that only half are very likely to get a COVID-19 vaccine, while one in three is either unlikely or unsure about it. The nationwide survey was a collaboration between The Leukemia & Lymphoma Society (LLS), Boston...
Why Might Night-Shift Workers Have a Higher Risk of Developing Cancer?
New clues as to why night-shift workers are at an increased risk of developing certain types of cancer were uncovered in a new study published by Koritala et al in the Journal of Pineal Research. The study involved a controlled laboratory experiment that used healthy volunteers who were on...
Responses to Conjugate Pneumococcal Vaccine in Patients With Chronic Lymphocytic Leukemia
In an Italian study reported in Leukemia, Mauro et al found that only a small minority of patients with chronic lymphocytic leukemia (CLL) developed an adequate immune response to pneumococcal vaccination, with response being more likely in patients who were younger, had previously untreated and...
Repurposing Available Drugs for COVID-19: An Ongoing Initiative
As of this writing, no drugs have been approved by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19, although several have received emergency use authorization and many others are being used off-label during the pandemic. In addition to searching for novel therapies, David...
Effect of Risk-Adapted Therapy on Long-Term Morbidity in Pediatric Patients With Hodgkin Lymphoma
In an analysis from the Childhood Cancer Survivor Study reported in the Journal of Clinical Oncology, Kevin C. Oeffinger, MD, and colleagues found that adoption of risk-adapted therapy in the 1990s was associated with reduced risk of serious chronic health conditions in pediatric Hodgkin lymphoma...
FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
On March 10, the U.S. Food and Drug Administration (FDA) approved tivozanib (Fotivda), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. TIVO-3 Efficacy was evaluated in TIVO-3 (ClinicalTrials.gov...
New Research Statement Recommends Streamlining and Standardizing Clinical Trial Site Feasibility Assessments
Feasibility assessments for clinical trials are conducted to establish that prospective trial sites can safely and effectively meet study goals and protocol requirements; however, a new research statement from ASCO asserts that current standards are “costly, inconsistent, inefficient, labor...
ASCO and Friends of Cancer Research Recommend Expanding Patient Access to Cancer Clinical Trials by Further Broadening Eligibility Criteria
ASCO and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients.1 The joint recommendations are detailed in a series of articles...
Expert Point of View: Roy S. Herbst, MD, PhD, FACP, FASCO, and Shinichi Toyooka, MD
The ASCO Post reached out to Roy S. Herbst, MD, PhD, FACP, FASCO, Chief of Medical Oncology and Associate Cancer Center Director for Translational Research at Yale Cancer Center and Smilow Cancer Hospital, New Haven, for his thoughts on the LCMC3 trial of neoadjuvant atezolizumab.1 Dr. Herbst led...
Neoadjuvant Atezolizumab in Lung Cancer: LCMC3 Trial Meets Primary Endpoint
Neoadjuvant treatment with single-agent atezolizumab in patients with stage IB to IIIB lung cancer resulted in a major pathologic response rate of 21% and a pathologic complete response rate of 7%, in the primary analysis of the Lung Cancer Mutation Consortium 3 (LCMC3) study.1 The findings were...
Belantamab Mafodotin-blmf Plus Pomalidomide and Dexamethasone Elicits Responses in Myeloma
Belantamab mafodotin-blmf combined with pomalidomide and dexamethasone led to a very good partial response or better in approximately three-quarters of patients with multiple myeloma that was double-class or triple-class refractory, according to Suzanne Trudel, MSc, MD, FRCPC, of Princess Margaret...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
Oncologist Survey Identifies Knowledge Gaps in Cholangiocarcinoma Mutations
In the treatment of cholangiocarcinoma, many clinicians may be unaware of the importance of the major oncogenic mutations and other alterations that can be identified and targeted, according to a survey of oncologists presented at the 2021 Gastrointestinal Cancers Symposium.1 “Recent developments...
Study Finds More Than Half of Cancer Survivors Have Underlying Medical Conditions Associated With Developing Severe COVID-19
A new study found that more than half (56.4%) of cancer survivors in the United States reported having additional underlying medical conditions associated with severe COVID-19 illness.1 The report, appearing in JNCI: The Journal of the National Cancer Institute, suggests that the prevalence of...
Fallout From COVID-19: Decline in Cancer Screening and Increase in Cancer-Related Deaths
Various studies at institutions in the United States and abroad have shown a substantial decline in cancer screening rates during the COVID-19 pandemic, suggesting that fewer cancers will be detected by screening and when they do manifest, they will be at more advanced stages. Indeed,...
